Travere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 5,375 Shares of Stock

Posted by Francis Steltz on Sep 18th, 2026

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) CAO Sandra Calvin sold 5,375 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.33, for a total value of $335,023.75. Following the transaction, the chief accounting officer directly owned 42,353 shares of the company’s stock, valued at $2,639,862.49. This represents a 11.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Up 2.0%

NASDAQ:TVTX opened at $64.74 on Friday. Travere Therapeutics, Inc. has a one year low of $22.06 and a one year high of $68.73. The company has a debt-to-equity ratio of 24.58, a current ratio of 4.05 and a quick ratio of 3.99. The company’s 50-day simple moving average is $61.63 and its 200 day simple moving average is $48.50. The firm has a market capitalization of $6.10 billion, a P/E ratio of -140.74 and a beta of 1.05.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03. Travere Therapeutics had a negative net margin of 7.35% and a negative return on equity of 55.15%. The business had revenue of $169.58 million during the quarter, compared to the consensus estimate of $157.27 million. During the same quarter last year, the firm earned $0.13 earnings per share. The business’s revenue for the quarter was up 48.2% on a year-over-year basis. As a group, analysts forecast that Travere Therapeutics, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TVTX. GAMMA Investing LLC lifted its holdings in shares of Travere Therapeutics by 53.4% during the 2nd quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock valued at $34,000 after buying an additional 211 shares during the period. Allworth Financial LP bought a new stake in shares of Travere Therapeutics in the second quarter worth $47,000. Fifth Third Bancorp purchased a new stake in Travere Therapeutics during the first quarter valued at $35,000. Integrated Wealth Concepts LLC purchased a new stake in Travere Therapeutics during the second quarter valued at $70,000. Finally, IFP Advisors Inc lifted its holdings in Travere Therapeutics by 11,770.0% in the fourth quarter. IFP Advisors Inc now owns 2,374 shares of the company’s stock valued at $91,000 after acquiring an additional 2,354 shares during the period.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on TVTX shares. Piper Sandler reissued an “overweight” rating on shares of Travere Therapeutics in a research note on Monday, August 17th. Evercore set a $78.00 target price on shares of Travere Therapeutics in a research note on Monday, August 10th. Wells Fargo & Company increased their price target on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a report on Friday, June 12th. Guggenheim boosted their price objective on shares of Travere Therapeutics from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings downgraded Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $68.00.

Get Our Latest Research Report on Travere Therapeutics

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.